Abstract
Background
Macroscopic portal vein thrombosis (PVT) is a common and dire prognostic feature of patients with hepatocellular carcinoma (HCC) and often precludes many treatments as a result. Little is known about its causes or mechanisms or clinical associations.
Aims
To examine patients with PVT in order to possibly identify prognostically different subsets.
Methods
A large cohort of non-curable patients with advanced and biopsy-proven HCC in which survival was documented, were retrospectively examined.
Results
We analyzed a large HCC cohort containing 366 (63.3 %) PVT-positive patients and found that PVT is associated with patients having larger tumors and higher levels of alpha-fetoprotein (AFP) and des-gamma carboxyprothrombin (DCP). We identified in patients with normal bilirubin levels (≤2.0 mg/dl) two PVT-positive patients, having higher and lower AFP levels, respectively. They differed in the significantly better prognosis of the low AFP patients, which may be useful for patient management decisions.
Conclusions
Patients with PVT are heterogeneous with respect to AFP levels. AFP-negative patients have a significantly better survival than those who have elevated AFP.
Similar content being viewed by others
Abbreviations
- HCC:
-
Hepatocellular carcinoma
- PVT:
-
Portal vein thrombosis
- AFP:
-
Alpha-fetoprotein
- DCP:
-
Des-gamma carboxyprothrombin
- GGT:
-
Gamma glutamyl transpeptidase
- ALKP:
-
Alkaline phosphatase
- AST:
-
Aspartate aminotransferase
- Hb:
-
Hemoglobin
- MTD:
-
Maximum tumor diameter
- CT:
-
Computerized axial tomography
- MRI:
-
Magnetic resonance imaging
References
Schöniger-Hekele M, Müller C, Kutilek M, Oesterreicher C, et al. Hepatocellular carcinoma in Central Europe: prognostic features and survival. Gut. 2001;48:103–109.
Kinoshita A, Onoda H, Fushiya N, Koike K, et al. Staging systems for hepatocellular carcinoma: current status and future perspectives. World J Hepatol. 2015;7:406–424.
Carr BI, Pancoska P, Branch RA. Tumor and liver determinants of prognosis in unresectable hepatocellular carcinoma: a large case cohort study. Hepatol Int. 2009;4:396–405.
Pirisi M, Avellini C, Fabris C, Scott C, et al. Portal vein thrombosis in hepatocellular carcinoma: age and sex distribution in an autopsy study. J Cancer Res Clin Oncol. 1998;124:397–400.
Carr BI, Kanke F, Wise M, Satomura S. Clinical evaluation of lens culinaris agglutinin-reactive alpha-fetoprotein and des-gamma-carboxyprothrombin in histologically proven hepatocellular carcinoma in the United States. Dig Dis Sci. 2007;52:776–782.
Hagiwara S, Kudo M, Kawasaki T, Nagashima M, et al. Prognostic factors for portal venous invasion in patients with hepatocellular carcinoma. J Gastroenterol. 2006;41:1214–1219.
Gotoh M, Nakatani T, Masuda T, Mizuguchi Y, et al. Prediction of invasive activities in hepatocellular carcinomas with special reference to alpha-fetoprotein and des-gamma-carboxyprothrombin. Jpn J Clin Oncol. 2003;33:522–526.
Koike Y, Shiratori Y, Sato S, Obi S, et al. Des-gamma-carboxyprothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer. 2001;91:561–569.
Carr BI, Kondragunta V, Buch SC, Branch RA. Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study. Cancer. 2010;116:1305–1314.
Taylor CR. Computed tomography in the evaluation of the portal venous system. J Clin Gastroenterol. 1992;14:167–172.
Tublin ME, Dodd GD 3rd. Baron RL Benign and malignant portal vein thrombosis: differentiation by CT characteristics. AJR Am J Roentgenol. 1997;168:719–723.
Rossi S, Ghittoni G, Ravetta V, et al. Contrast-enhanced ultrasonography and spiral computed tomography in the detection and characterization of portal vein thrombosis complicating hepatocellular carcinoma. Eur Radiol. 2008;18:1749–1756.
Zeng ZC, Fan J, Tang ZY, Zhou J, et al. Prognostic factors for patients with hepatocellular carcinoma with macroscopic portal vein or inferior vena cava tumor thrombi receiving external-beam radiation therapy. Cancer Sci. 2008;99:2510–2517.
Yamamoto Y, Ikoma H, Morimura R, Shoda K, et al. Post-hepatectomy survival in advanced hepatocellular carcinoma with portal vein tumor thrombosis. World J Gastroenterol. 2015;21:246–253.
Le Treut YP, Hardwigsen J, Ananian P, Saïsse J, et al. Resection of hepatocellular carcinoma with tumor thrombus in the major vasculature. A European case-control series. J Gastrointest Surg. 2006;10:855–862.
Zeng ZC, Fan J, Tang ZY, Zhou J, et al. Prognostic factors for patients with hepatocellular carcinoma with macroscopic portal vein or inferior vena cava tumor thrombi receiving external-beam radiation therapy. Cancer Sci. 2008;99:2510–2517.
Cheong JY, Lee KM, Cho SW, Won JH, et al. Survival benefits of intra-arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis. Hepatol Res. 2005;32:127–133.
Kim JM, Kwon CH, Joh JW, Ko JS, et al. C-reactive protein may be a prognostic factor in hepatocellular carcinoma with malignant portal vein invasion. World J Surg Oncol. 2013;11:92.
Chok KS, Cheung TT, Chan SC, Poon RT, et al. Surgical outcomes in hepatocellular carcinoma patients with portal vein tumor thrombosis. World J Surg. 2014;38:490–496.
Ye JZ, Zhang YQ, Ye HH, Bai T, et al. Appropriate treatment strategies improve survival of hepatocellular carcinoma patients with portal vein tumor thrombus. World J Gastroenterol. 2014;20:17141–17147.
Kulik LM, Carr BI, Mulcahy MF, Lewandowski RJ, et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology. 2008;47:71–81.
Lau WY, Sangro B, Chen PJ, Cheng SQ, et al. Treatment for hepatocellular carcinoma with portal vein tumor thrombosis: the emerging role for radioembolization using yttrium-90. Oncology. 2013;84:311–318.
Kokabi N, Camacho JC, Xing M, El-Rayes BF et al. Open-label prospective study of the safety and efficacy of glass-based yttrium 90 radioembolization for infiltrative hepatocellular carcinoma with portal vein thrombosis. Cancer. 2015. doi:10.1002/cncr.29275.
No authors. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology. 1998;28:751–5.
Carr BI, Guerra V, Giannini EG, Farinati F, et al. Association of abnormal plasma bilirubin with aggressive hepatocellular carcinoma phenotype. Semin Oncol. 2014;41:252–258.
Carr BI, Lin CY, Lu SN. Platelet-related phenotypic patterns in hepatocellular carcinoma patients. Semin Oncol. 2014;41:415–421.
Carr BI, Guerra V, Giannini EG, Farinati F, et al. Significance of platelet and AFP levels and liver function parameters for HCC size and survival. Int J Biol Markers. 2014;29:e215–e223.
Xu XS, Wan Y, Song SD, Chen W, et al. Model based on γ-glutamyltransferase and alkaline phosphatase for hepatocellular carcinoma prognosis. World J Gastroenterol. 2014;20:10944–10952.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
None.
Rights and permissions
About this article
Cite this article
Carr, B.I., Guerra, V. Low Alpha-Fetoprotein Levels Are Associated with Improved Survival in Hepatocellular Carcinoma Patients with Portal Vein Thrombosis. Dig Dis Sci 61, 937–947 (2016). https://doi.org/10.1007/s10620-015-3922-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-015-3922-3